Compare Goldman Sachs Physical Gold ETF (AAAU) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Physical Gold ETF vs Ascendis Pharma A/S — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.58, while Ascendis Pharma A/S trades at $255.85 (market cap $16.67B). The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Goldman Sachs Physical Gold ETF nearer its low. Which is the better fit depends on your goals.
| AAAU | ASND | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $277.18 |
52-Week Low | $32.74 | $189.74 |
Market Cap | — | $16.67B |
Enterprise Value | — | $17.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused stock, trades at $43.73, up 1.06% with a bullish technical signal from moving averages but bearish oscillators. Recent news highlights gold's strength amid cooling US inflation and geopolitical tensions, with spot gold reaching $4,438/oz (Kitco, 2026-08-12). Financial ratios are unavailable, limiting fundamental clarity.
The outlook is mixed: technical momentum supports near-term gains, but overbought RSI levels suggest caution. Gold's appeal as a safe-haven asset amid economic uncertainty offers upside, yet reliance on commodity prices and absent financial metrics pose risks for stock investors.
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goldman Sachs Physical Gold ETF
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
